Affimed (AFMD) Reports Q4 Loss of EUR0.60/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Affimed (AFMD) Reports FY22, Provides Operational Update
March 23, 2023 6:31 AM EDTAffimed N.V. (Nasdaq: AFMD) today reported financial results for the year ended December 31, 2022, and provided an update on clinical and corporate progress.
During 2022, we presented data across our pipeline that show our innate cell engagers can deliver unprecedented efficacy when combined with NK cells, can activate and direct cytotoxic T cells to tumor cells, and deliver meaningful single agent activity with a differentiated safety profile, said Adi Hoess, Chief Executive Officer at Affimed. Supported by a cash runway into 2025, our Company is well positioned to execute on our strategic imperatives, with... More
